Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences.

Scientific reports - 2 Jun 2020

Gerstenberger Brian S, Banker Mary Ellen, Clark James D, Dowty Martin E, Fensome Andrew, Gifford Roger, Griffor Matthew C, Hegen Martin, Hollingshead Brett D, Knafels John D, Lin Tsung H, Smith James F, Vajdos Felix F

Abstract excerpt

Translation of modulation of drug target activity to therapeutic effect is a critical aspect for all drug discovery programs. In this work we describe the profiling of a non-receptor tyrosine-protein kinase (TYK2) inhibitor which shows a functionally relevant potency shift between human and preclinical species (e.g. murine, dog, macaque) in both biochemical and cellular assays. Comparison of the structure and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenosine Triphosphate
Share to Dogs

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Discovery

Share to Janus Kinase 1

Share to Macaca

Share to Protein Domains

Share to Protein Kinase Inhibitors

Share to TYK2 Kinase

Source

Open in PubMed Open full text

Identifiers

PMID: 32488071
DOI: 10.1038/s41598-020-65762-y
PMCID: PMC7265552

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Demonstration of In Vitro to In Vivo Translation of a TYK2 Inhibitor That Shows Cross Species Potency Differences.PMID 32488071Read ↗

A whole-animal platform to advance a clinical kinase inhibitor into new disease spaceSemantic proximity Read ↗

Deep mutational scanning reveals pharmacologically relevant insights into TYK2 signaling and diseaseSemantic proximity Read ↗

Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogenySemantic proximity Read ↗

Deep mutational scanning reveals pharmacologically relevant insights into TYK2 signaling and disease.Semantic proximity Read ↗

Reprogramming protein kinase substrate specificity through synthetic mutationsSemantic proximity Read ↗

Biomolecular study of human thymidylate synthase conformer-selective inhibitors: New chemotherapeutic approach.Semantic proximity Read ↗

Discovery of G2019S-Selective Leucine Rich Repeat Protein Kinase 2 inhibitors with in vivo efficacy.Semantic proximity Read ↗

Discovery of (E)-N-(4-methyl-5-(3-(2-(pyridin-2-yl)vinyl)-1H-indazol-6-yl)thiazol-2-yl)-2-(4-methylpiperazin-1-yl)acetamide (IHMT-TRK-284) as a novel orally available type II TRK kinase inhibitor capable of overcoming multiple resistant mutants.Semantic proximity Read ↗

Discovery and Structure–Activity Relationship of Potent and Selective Covalent Inhibitors of Transglutaminase 2 for Huntington’s DiseaseSemantic proximity Read ↗

Substrate-derived peptides for selective covalent inhibition of protein tyrosine kinasesSemantic proximity Read ↗

Human thymidylate synthase with loop 181-197 stabilized in an inactive conformation: ligand interactions, phosphorylation, and inhibition profiles.Semantic proximity Read ↗

In depth analysis of kinase cross screening data to identify chemical starting points for inhibition of the nek family of kinasesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.